DXCM · DexCom, Inc. · Stock research

Current Thesis

The July 30 print was the gate this coverage had flagged, and it cleared. Q2 revenue came in at $1.3084B against a $1.290B consensus, +13% reported and +12% organic; adjusted EPS $0.70 versus $0.61 expected. FY2026 revenue guidance moved to $5.180–5.250B from $5.160–5.250B, non-GAAP operating margin guidance to 23.5–24% from 23–23.5%, and non-GAAP gross margin guidance to roughly 64%. Ten sell-side target raises carry the date 7/31 — Mizuho, Piper Sandler and Stifel each to $95, Truist $93, RBC/Wells Fargo/BTIG/Canaccord-adjacent names at $90, Citi $88, and JP Morgan (Neutral) and Benchmark both at $82 — followed by Canaccord $90 on 8/3 and Argus $96 on 8/4. The pipeline's adjusted basis puts the last completed close at $84.75 (2026-08-07), 2.9% under the $87.31 52-week high, RSI(14) 65.1, +39.8% over three months. The mid-July structure — a recovery bounce still working a long-term moving average from below at a $76.65 close on 7/17 — has been replaced by a gap-driven advance in the top decile of its 52-week range. Life-cycle: ACCELERATING, dated by the 7/30 print and the 7/31–8/4 revision cluster. The qualifier is the calendar: no company-confirmed event falls between 2026-08-09 and 2026-09-08, and the next hard binary is the Q3 report expected around 2026-10-29.

Bullish and bearish views on DexCom, Inc.

The model's bull view on DexCom, Inc. (DXCM), in brief: The guide moved up on both lines, 7/30. FY26 revenue floor lifted to $5.180B from $5.160B (11–13% growth), non-GAAP operating margin to 23.5–24% from 23–23.5%. Margin was the raise the market had not been carrying. Gross margin expansion is measured, not promised. Q2 non-GAAP… The bear view: The raise was one-sided. Only the bottom of the FY26 range moved ($5.160B → $5.180B); the $5.250B top was left untouched, and the range brackets the $5.224B consensus figure. A guide that lifts the floor and not the ceiling is a de-risking, not an acceleration. Two published… Both cases follow in full.

Bull Case

• The guide moved up on both lines, 7/30. FY26 revenue floor lifted to $5.180B from $5.160B (11–13% growth), non-GAAP operating margin to 23.5–24% from 23–23.5%. Margin was the raise the market had not been carrying.
• Gross margin expansion is measured, not promised. Q2 non-GAAP gross margin 64.1% versus 60.1% a year earlier — 400bp — attributed on the call to manufacturing efficiencies and normalized shipping patterns. FY gross margin guidance moved to ~64%.
• International is outgrowing the base. Q2 international revenue +19% reported / +16% organic against US +11%, on the 7/30 release. The geographic leg (G7 15 Day authorized by Health Canada 7/13/2026, 15.5-day wear, 8.0% MARD) is doing work independent of US payer dynamics.
• Capital return ran at scale into the drawdown. $600M of stock repurchased during Q2 under a $1B FY2026 authorization, per the 7/30 release — two-thirds of the year's authorization spent in a single quarter that began with the stock in the $60s–$70s.
• The revision wave extended past the print week. Canaccord to $90 (8/3) and Argus to $96 (8/4) landed three and four sessions after the cluster, so the bid was not confined to the 48-hour reaction window.
• Type 2 non-insulin remains the unpenetrated cohort. CONNECT (reported 6/8/2026) showed G7 cutting A1C 1.6% over 26 weeks in Type 2 patients not on insulin; management framed coverage progress for that cohort as a 2026 priority on the 7/30 call.

Bear Case

• The raise was one-sided. Only the bottom of the FY26 range moved ($5.160B → $5.180B); the $5.250B top was left untouched, and the range brackets the $5.224B consensus figure. A guide that lifts the floor and not the ceiling is a de-risking, not an acceleration.
• Two published targets sit under the tape. JP Morgan (Neutral, $82) and Benchmark ($82), both dated 7/31, are below the 8/7 close of $84.75. The band from there to the highest print, Argus $96 (8/4), is where the whole reward argument lives.
• Supply into strength is documented. A family trust tied to director Mark G. Foletta sold 2,000 shares at $80.00 on 7/31 and 2,000 shares at $85.32 on 8/3, per Form 4 — pre-arranged under a 10b5-1 plan adopted 3/13/2026, so not a discretionary view, but stock hitting the market at the highs all the same.
• An eleven-week hole in the calendar. With ADA (6/5–8), CONNECT (6/8), the OTC pediatric / Stelo expansion (6/15) and the Q2 print all behind it, the name has no company-confirmed catalyst until the Q3 report around 10/29. Revision-driven legs decay when there is nothing new to revise against.
• Clinical data is not reimbursement. The Type 2 non-insulin TAM converts only on payer coverage, which historically lags trial readouts by several quarters; no broad national coverage decision has been announced.
• The structural overhang did not go away. Abbott's Libre pricing and share, pump-integration slots at Insulet and Tandem, and GLP-1 displacement (Lilly, Novo) remain the questions under the whole CGM complex, and none of them were settled by a single quarter's beat.

Setup & Price Structure

• Last completed close $84.75 (2026-08-07); 52-week high $87.31; distance to high −2.9%; RSI(14) 65.1; three-month return +39.8%.
• The 7/30 print produced the volume expansion the June advance lacked — that earlier leg ran near 0.74x average volume, which was the specific reason this note treated it as an unconfirmed bounce rather than a trend.
• The pre-print congestion sits in the mid-to-high $70s: $77.98 close on 7/16 after the Mizuho/Truist raises, $76.65 on 7/17. The 7/30 gap left that shelf behind; a return into it would erase the earnings reaction entirely.
• Crowding observables, stated as observables: twelve target changes inside five sessions (7/31–8/4); RSI(14) 65.1 with price within 3% of the 52-week high; retail-facing coverage clustering on the beat (multiple same-week "jumps after earnings" write-ups dated 8/1–8/2); insider stock sold into the move on 7/31 and 8/3 under a pre-existing plan. Cutting the other way: there is no earnings date inside 30 days, so the near-term event risk that normally accompanies this kind of extension is absent.
• What would convert ACCELERATING to MATURING: the revision cluster completing with no follow-on datapoint — a named payer coverage decision, a product clearance, a competitive share disclosure — before the Q3 print.

Catalyst Calendar (next 30 days)

• 2026-08-09 → 2026-09-08: no company-confirmed event. The window is empty. Any move inside it is flow and sector beta, not company news.
• ~2026-10-29 (est.) — Q3 2026 earnings, after the close. Outside the 30-day window and the next hard binary; consensus EPS around $0.67 per aggregator listings. DexCom has historically confirmed the date roughly three weeks ahead.
• Undated, live — payer coverage announcements for Type 2 non-insulin patients, and any Abbott disclosure on Libre pricing or share. Neither carries a scheduled date; both would re-price the name on the day they land.

What Would Change Our Mind

The structure that matters is the July 30 gap. Everything above the mid-$70s was created by one session's reaction to one quarter, and the pre-print range is still sitting directly underneath it. A daily close below $77 would close that gap and put price back inside the range it occupied when the setup was still a bounce contending with a long-term average from below — at which point the revision wave dated 7/31–8/4 becomes a sold-into event rather than the start of a leg. Two secondary conditions would compound it: the Q3 date passing around 10/29 without a second consecutive guidance raise (particularly a failure to move the $5.250B FY ceiling), and a named competitive or reimbursement headline — an Abbott Libre price action, or a payer declining Type 2 non-insulin coverage — that removes the datapoint the bull case is waiting on. A move to fresh 52-week highs above $87.31 on volume, by contrast, would argue the re-rating has further to run and that the $82 targets are the ones that get revised.

Correlation Notes

• Abbott (ABT) is the direct read: Libre pricing and share commentary at ABT's quarterly prints moves the CGM complex on the same tape.
• Insulet (PODD), Tandem (TNDM) — pump-integration partners whose sensor-partner disclosures cut both ways for DXCM's attach rate.
• Eli Lilly (LLY), Novo Nordisk (NVO) — GLP-1 headlines are the structural swing factor the CGM complex has traded against since 2023; incretin news flow has repeatedly moved DXCM without any DXCM-specific news.
• Medtech beta (IHI, XLV) — a high-multiple, mid-teens-growth medtech re-rating is rate- and risk-appetite-sensitive; the 39.8% three-month advance ran alongside a broadly bid market, which is not separable from company-specific alpha at this sample size.